arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

BIO-TECHNE Corp

TECH
$72.30 ▲ +0.38 (+0.52%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
69 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
72
Health
Good
Neutral
auto_awesome

Analytical Summary

BIO-TECHNE Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $11.3B
Dividend Yield 0.11%
Revenue Growth -1.5%
Op. Margin 24.2%
ROIC 2.6%
FCF / Share $0.50
Trailing P/E 219.1x
Price / Book 5.4x
FCF Yield 0.7%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

69-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$311.42M
↓ -1.5%
Net Income Profit after all expenses
$51.05M
↑ +126.0%
Operating Margin Operating profit as % of sales
24.2%
↑ +31.7% 52th
FCF / Share Free cash flow per share
$0.50
↑ +1.1%

Health Breakdown

Profitability
63
Financial Health
74
Cash Quality
93

Dividend History

Dividend / share · sourced from SEC filings
$0.32 Latest / share
+0.0% YoY
+0.4% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 69 quarters